Navigation Links
Spherix to Exhibit at the BIO 2009 International Convention
Date:5/14/2009

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will exhibit at the 2009 BIO International Conference in Atlanta, Georgia on May 18-21, 2009.

Spherix's "Naturlose: A New Diabetes and Obesity Control Drug" booth will showcase their ongoing global phase 3 clinical trial for the use of Naturlose(R) as a treatment for Type 2 diabetes. The Company will be at booth #3805 in the Maryland Pavilion, Level 1, Section B3, Building B Exhibition Hall.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Spherix Announces 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
(Date:2/10/2016)... 2016  The Maryland House of Delegates and House ... University of Maryland School of Medicine Dean E. ... Maryland Medical System President and CEO Robert Chrencik ... highest honor given to the public by the leader ... Reece and Mr. Chrencik for their contributions to ...
(Date:2/10/2016)... York (PRWEB) , ... February ... ... (NASDAQ: REGN) today announced that it has joined the Human Vaccines Project, ... for infectious diseases and cancer. , The Human Vaccines Project brings ...
(Date:2/10/2016)... 2016  Matchbook, Inc., a company specializing in ... companies, announced today the appointment of Jim ... brings nearly 25 years of experience in supply ... nearly two decades in executive level roles as ... Genzyme and, most recently headed global logistics and ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)...   Parabon NanoLabs (Parabon) announced today ... Office and the Defense Forensics and Biometrics Agency ... company,s Snapshot Kinship Inference software for ... defense-related DNA forensics.  Although Snapshot is best known ... ancestry from DNA evidence), it also has the ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
Breaking Biology News(10 mins):